Summary
Cardinal Health Inc. (CAH) has announced an upward revision to its fiscal year 2025 non-GAAP diluted earnings per share (EPS) guidance. The company now expects its non-GAAP EPS to be toward the high end of its previously stated range of $7.75 to $7.90. This positive adjustment is primarily attributed to the sustained strong performance within its Pharmaceutical and Specialty Solutions segment. Investors should note that the company will be presenting at the JP Morgan 43rd Annual Healthcare Conference on January 14, 2025, where further commentary on this update is expected. Additionally, more comprehensive details regarding fiscal year 2025 expectations will be provided during the second quarter earnings call scheduled for January 30, 2025. The company emphasizes that it does not provide forward-looking guidance on a GAAP basis due to the unavailability of certain significant financial information.
Key Highlights
- 1Cardinal Health raises FY2025 non-GAAP EPS outlook to the high end of the $7.75-$7.90 range.
- 2The positive revision is driven by strong performance in the Pharmaceutical and Specialty Solutions segment.
- 3The company will provide further commentary on this update at the JP Morgan Healthcare Conference on January 14, 2025.
- 4Additional details on FY2025 expectations will be shared during the Q2 earnings call on January 30, 2025.
- 5Cardinal Health does not provide forward-looking guidance on a GAAP basis.
- 6The filing includes standard cautionary statements regarding forward-looking statements and associated risks.